Allecra Therapeutics has obtained positive Phase II study results for its new urinary tract infection antibiotic, supporting the launch of a Phase III trial.
Allecra Therapeutics, a French-German biotech, has obtained positive Phase II trial results for its lead antibiotic candidate for treating urinary tract infections. The drug, AAU101, was given to patients intravenously with cefepemine, another antibiotic used to treat urinary tract infections. The trial results show that the antibiotic combination was more effective in reducing disease-causing bacteria compared to the use of cefepemine alone.
AAU101 inhibits β-lactamase enzymes, a group of enzymes that confer resistance to certain antibiotics, including penicillin. Bacteria that carry β-lactamase are prevalent in hospitals across the globe and antibiotic resistance is a growing problem in treating them.
Earlier this year, Allecra obtained a Fast Track Designation from the FDA to move AAU101 into Phase III trials.
Image by Vintage Tone/Shutterstock